Figure 3. RO4929097 suppressed the relative expression of osteoclastogenesis genes. (A) BMMs were treated with M-CSF (33.3 ng/mL), RANKL (100 ng/mL) in the presence of 0, 100, 200, and 400 nM RO4929097 for five days. The expression of the osteoclast-specific genes, including NFATc1, Cath-K, TRAP, and C-fos were analyzed using quantitative real-time PCR. (B) The BMMs were treated with M-CSF (33.3 ng/mL) and RANKL (100 ng/mL) in the presence 400 nM RO4929097 for 1, 3, and 5 days. Osteoclast-specific gene expression was analyzed using quantitative real-time PCR. RNA expression levels were normalized to the expression of GAPDH. The data were presented as the mean ± SD (*p < 0.05; **p < 0.01; ***p < 0.001).